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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).SUMMARYBone marrow stromal cells (BMSCs, also called bone-marrow-derived mesenchymal stromal cells) provide hematopoietic support and
immunoregulation and contain a stem cell fraction capable of skeletogenic differentiation. We used immortalized human BMSC clonal
lines for multi-level analysis of functional markers for BMSC subsets. All clones expressed typical BMSC cell-surface antigens; however,
clones with trilineage differentiation capacity exhibited enhanced vascular interaction gene sets, whereas non-differentiating clones
were uniquely CD317 positive with significantly enriched immunomodulatory transcriptional networks and high IL-7 production.
IL-7 lineage tracing and CD317 immunolocalization confirmed the existence of a rare non-differentiating BMSC subtype, distinct
from Cxcl12-DsRed+ perivascular stromal cells in vivo. Colony-forming CD317+ IL-7hi cells, identified at 1%–3% frequency in hetero-
geneous human BMSC fractions, were found to have the same biomolecular profile as non-differentiating BMSC clones using Raman
spectroscopy. Distinct functional identities can be assigned to BMSC subpopulations, which are likely to have specific roles in immune
control, lymphopoiesis, and bone homeostasis.INTRODUCTION
Bone marrow stromal cells (BMSCs, also called bone-
marrow-derived mesenchymal stromal cells) are hetero-
geneous populations that likely contain varying levels
of tripotent (osteogenic, adipogenic, and chondrogenic
[OAC]) stem-cell-like cells; cells with restricted potency
(bi-, uni-, and nullipotent), committed precursors, and
other stromal cell types. Phenotypic variations probably
reflect in vivo functional diversity and a biological require-
ment for distinct stromal subsets with specific roles in
bonemarrowmaintenance. Single-cell-derived BMSC clone
analysis has identified considerable variation in differentia-
tion capacity, ranging fromOAC tripotency to nullipotency
in vitro (Muraglia et al., 2000; Okamoto et al., 2002; Russell
et al., 2010, 2011) and in vivo (Kuznetsov et al., 1997),
which may indicate the existence of BMSC subtypes with
varied potencies and/or a hierarchical developmental pro-
gression. BMSCs also possess significant immunomodula-
tory characteristics and can influence all aspects of immune
cell function via cell-cell interaction and immunoregulatory
factor secretion (Nauta and Fibbe, 2007), although clear
demarcation between the skeletogenic and immunomodu-
latory capacity of BMSCs has not been made. Identification
of human BMSCs often relies on non-discriminatory
epitope detection (such as CD29, CD44, CD73, CD901004 Stem Cell Reports j Vol. 4 j 1004–1015 j June 9, 2015 j ª2015 The Aut[THY-1], CD105, CD106 [VCAM-1], and CD166) with lack
of hematopoietic markers (such as CD34, CD14, and
CD45) (Dominici et al., 2006). Additional BMSC surface an-
tigens have been described, including STRO-1 (Simmons
and Torok-Storb, 1991), CD146 (MCAM) (Sacchetti et al.,
2007), CD271 (LNGFR) (Quirici et al., 2002), Nestin (Me´n-
dez-Ferrer et al., 2010), platelet-derived growth factor recep-
tor alpha (PDGFRa)/CD51 (Pinho et al., 2013), LNGFR+THY-
1+VCAM-1hi+ (Mabuchi et al., 2013), and in mice, leptin
receptor (LepR/CD295) (Zhou et al., 2014). However, cell-
sorting experiments using these markers all show that
they contain the colony-forming, differentiation-compe-
tent BMSC population, demonstrating that other, as yet
undefined BMSC subtypes exist and further resolution of
BMSC heterogeneity is required. In vitro studies of BMSC
functionality are hindered by their limited lifespan as
replicative senescence occurs during culture, thus limiting
the number and depth of studies that can be performed.
To address these issues, we immortalized human BMSCs
using human telomerase reverse transcriptase (hTERT),
followed by clonal isolation to generate a panel of BMSC
lines (hTERT-BMSCs). This strategy enabled in-depth,
multiparameter analysis of variation in human BMSC
subpopulations with different behavioral traits that sub-
sequently could be examined in heterogeneous primary
BMSCs. We unveil a range of biophysico-chemical markershors
for identification of different BMSC subsets with specific
immunomodulatory and differentiation competencies.RESULTS
Generation and Phenotyping of Variant hTERT
Immortalized Clonal Cell Lines from Primary BMSCs
A heterogeneous population of primary bone marrow
BMSCswas isolated from one donor (FH181) based on their
strong growth properties and multilineage differentiation
potential. A single donor was deliberately selected to guard
against expected genetic/lifestyle factors that cause inter-
donor variation and would cloud interpretation of BMSC
sub-population variation. A lentiviral expression system
was used to overexpress hTERT in these cells, and stable-
expressing lines were generated from single-cell-derived
colonies. From numerous hTERT-BMSCs generated, our
attention focused initially on four clonal lines selected for
their strong clonal and stable growth characteristics
(termed Y101, Y102, Y201, and Y202) that were main-
tained for over 400 days, showing exponential growth (Fig-
ure S1A) and elevated telomerase activity (Figure S1B).
Their BMSCmarker profile was determined by flow cytom-
etry; all were positive for CD29, CD44, CD73, CD90,
CD105, and CD166 and negative for CD34 and CD45
(Figure 1A), a profile matching their parental cells and
typical of human primary BMSCs. All clones were also
negative for CD11b, CD14, CD169, CD1a, CD4, CD11c,
and CD83 (data not shown). It has been suggested
previously that some BMSC lines may undergo oncogenic
transformation either through hTERT transduction or
extended time in culture (Serakinci et al., 2004). We found
no evidence of tumorigenicity in our hTERT-BMSCs using
in vitro colony transformation assays for non-adherent
growth (Figure S1C) or following subcutaneous injection
into immunocompromised mice (data not shown).
Distinct differences were observed in individual cell mor-
phologies and single-cell-derived colonies: Y101 and
Y201 shared characteristics that were distinct from Y102
and Y202 lines. Y101 and Y201 lines had elongated fibro-
blastoid morphology, typical of BMSCs, whereas Y102
and Y202 were flattened and spread.When plated at clonal
density, Y101/Y201 cells consistently formed dispersed col-
onies with low cell contact, characteristic of a migratory
phenotype, whereas Y102 and Y202 cells formed regular,
high-density, compact colonies (Figures 1B and S1D).
Morphological differences were quantified by image anal-
ysis, which demonstrated that Y202 cells had a statistically
significantly greater area and perimeter compared to both
the Y101 and Y201 cells. Y102 cells were also larger than
the Y101/Y201; the mean cell perimeters for Y102, Y202,
Y101, and Y201 were 273 ± 23, 317 ± 107, 202 ± 19, andStem C190 ± 34 mm, and mean cell areas were 1,537 ± 132,
1,649 ± 614, 1,067 ± 92, and 857 ± 214 mm2, respectively
(Figures S1E and S1F).
We identified variations in potency following OAC dif-
ferentiation assays (Figures 1C–1E). Adipogenic media for
up to 21 days induced the most potent observable and sta-
tistically significant adipogenic differentiation in Y201
cells at each time point, measured using the oil red O
lipid-staining assay (Figure 1C). Y101 was also observed
to differentiate into adipocytes, reaching significance at
day 21, but Y102 and Y202 showed severely limited,
although not completely absent, adipogenic potential,
whichwas significantly different to Y201 at day 21. In addi-
tion, there were statistically significant increases in the
levels of expression of the adipogenic genes peroxisome
proliferator-activated receptor (PPAR)-g and lipoprotein
lipase (LPL) in the Y201 cells cultured in adipogenic media
at day 14 and day 21 compared to the time-matched un-
treated controls. At day 21, the expression level of both
these genes was significantly lower in the three other cell
lines (Figure 1C). Y101 and Y201 differentiated convinc-
ingly along osteogenic lineages and showed elevated alka-
line phosphatase (ALP) activity with significantly increased
calcium deposition by alizarin red staining (Figure 1D),
which was statistically higher than Y102/Y202 clones,
which showed minimal mineral deposition, although
Y102 displayed elevated ALP activity (Figure 1D). Increases
in ALP activity observed under basal conditions for Y101
and Y201 were replicated in qPCR analyses of the ALP
gene (Figure S1G); further increases in ALP gene expression
were clearly evident in the Y101 cell line under osteogenic
conditions, while the levels in the other lines only showed
modest increases. Furthermore, histological staining for
elevated ALP activity was only observable in the Y101/
Y201 cells (Figure S1G). Gene expression analyses for
RUNX2 showed that only the Y101/Y201 cell lines upregu-
lated this early osteogenic marker at day 7 (Figure 1D). In
response to chondrogenic induction using transforming
growth factor b (TGF-b), only lines Y101 and Y201 dis-
played an early cell-condensation phenotype associated
with chondrogenic induction (Johnson et al., 2012),
whereas no condensation was observed in similar micro-
mass culture of lines Y102 and Y202 (Figure 1E). When cul-
tures were stained with alcian blue and stain-associated
glycosaminoglycans (GAGs) were eluted and quantified,
significantly different levels were observed in all cell lines
at day 9 compared to their time-matched controls under
basal conditions, but the highest and statistically signifi-
cant GAG levels were clearly evident in the Y101/Y201
compared to the Y102/Y202 cell lines. Similarly, only the
Y101 and Y201 lines displayed marked increases in total
GAG production under chondrogenic conditions in the
Blyscan GAG assay (Figure 1E). Gene expression analysesell Reports j Vol. 4 j 1004–1015 j June 9, 2015 j ª2015 The Authors 1005
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for the early chondrogenic marker SOX9 confirmed that
this marker only increased in the Y101/Y201 cell lines after
7 days in chondrogenic differentiation media (Figure 1E).
Therefore, lines Y101/Y201were capable of BMSCOAC dif-
ferentiation, with Y201 showing stronger adipogenesis.
The Y102/Y202 BMSC lines exhibited a non-hematopoiet-
ic, stromal phenotype with distinctive clonal behavior but
with atypical BMSC morphology and limited differentia-
tion ability compared to Y101/Y201.
Interrogation of Gene Expression Profiles Identifies
Immune-Related BMSC Subtypes
We performed global gene expression analyses to identify
distinguishing characteristics between the hTERT-BMSC
clones and parental BMSCs; selecting significantly differen-
tially expressed genes (p < 0.05, >2-fold change). Hierarchi-
cal clustering grouped Y101 with Y201 and closest to the
primary parent BMSCs, while Y102/Y202 clustered sepa-
rately (Figure 2A). Principal component analysis (PCA)
revealed that 70% of the total variance was captured by
the first two components (Figure S2A) and confirmed segre-
gation of Y102/Y202 BMSC lines from the Y101/Y201
BMSC lines, the parent BMSC (FH181), and other primary
BMSC populations (Figure S2B). Pathway analysis identi-
fied significant differences in expression of genes involved
in the cell cycle, DNA replication, and other processes
associated with cell replication, as would be predicted
when comparing hTERT-immortalized lines with the
parent sample (Figure 2B). Additional gene sets identified
were involved in cell adhesion, endochondral ossification,
and adipogenesis. Differentially expressed genes were
notably enriched in pathways involved in Toll-like recep-
tor, interferon, tumor necrosis factor a (TNF-a), inter-
leukin-7 (IL-7) signaling, and inflammatory responses,
implicating potential differences in the immunoregulatory
properties between these lines (Figure 2B). Patterns of gene
expression were also visualized and investigated using self-
organizing heatmaps (SOMs). Expression data were used to
produce mosaic fingerprints, and each mosaic tile repre-
sents metagenes that consist of mini-clusters of genesFigure 1. Generation and Analysis of hTERT-BMSC Clones
(A) Analysis of hTERT-BMSC clones (Y101, Y102, Y201, and Y202) b
Representative histograms are shown.
(B) Clonal growth of hTERT-BMSCs (crystal violet stain). Scale bars, 2
(C–E) Assessment of the OAC potential of hTERT-BMSC clones; repr
adipogenic (C), osteogenic (D), and chondrogenic supplements (E).
average quantified values ± SD for two or three independent exper
considered to be statistically significant after the data from n > 3 exper
comparisons if *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0
Additionally, one-way ANOVA with Holm Sidak’s comparisons was pe
differences compared with Y101 () or Y102 ($) and Y201 (#) are in
See also Figure S1.
Stem Cwith similar expression placed in the same position across
the mosaics (Figure 2C). Y101, Y201, Y102, and Y202 were
compared against the primary parent BMSC source
(FH181) and four others (FH469, FH348, FH359, and
FH392). Primary BMSCs showed consistent spots of strong
over- and under-expression in the bottom-right and
top-left corners, respectively. Y101/Y201 and Y102/Y202
hTERT-BMSCs showed differences in patterns of expression
at regions of over- and under-expression in the top right
and bottom left of the SOMs, respectively (Figure 2C,
arrows, and Figures S2C and S2D). The most significant
gene sets overexpressed in Y101/201 versus Y102/202
were related to vascular growth (blood vessel remodelling,
blood vessel development, artery morphogenesis, and
patterning of blood vessels; Figure S2C). Under-expressed
Y101/Y201 gene sets that were most significantly over-rep-
resented in Y102/Y202 lines were immunomodulatory (an-
tigen processing, MHC class II proteins, T cell signaling,
and responses to interferon; Figure S2D).
Further analysis found a strikingly elevated endogenous
expression of inflammation-induced genes in the non-
differentiating lines Y102 and Y202 compared to the
OAC-differentiation-competent BMSC clones (Figure 2D).
By analyzing gene expression changes reported in a previ-
ously published dataset, where global gene expression
was studied in adipose-derived BMSCs with or without
stimulation with inflammatory cytokines (interferon g
[IFN-g], TNF-a, and IL-6) (Crop et al., 2010), we found
that inflammation-induced genes were also elevated in un-
stimulated Y102 and Y202 cells compared to the Y101/
Y201 and parental BMSCs (Figure 2D). These observations
pointed to the existence of a non-differentiating, resident
stromal cell subset with ‘‘unlicensed’’ immunoregulatory
potential associated with a pro-inflammatory response.
The immunomodulatory effects of BMSCs are normally
reported to be related to immunosuppression. In assays of
immunosuppressive function, we found that all hTERT-
BMSC lines were similarly capable of inhibiting anti-
CD3/anti-CD28 antibody-stimulated peripheral blood
mononuclear cell (PBMC) proliferation with no significanty flow cytometry for surface markers typically assigned to BMSCs.
00 mm.
esentative images and quantification of cells differentiated with
Scale bar represents 200 mm (C and D) or 2 mm (E). Data represent
iments performed using two to six replicates. Differentiation was
iments were analyzed by one-way ANOVA with Holm Sidak’s multiple
.0001 between both day 0 and the time-matched basal control.
rformed between the different cell lines at day 21, and significant
dicated.
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Figure 2. Expression Profiling Identifies BMSC Clones with Distinct Immunoregulatory Features
(A) Hierarchical clustering heatmap of global gene expression profiles from each hTERT-BMSC clonal line and the parental BMSCs.
(B) Pathway analysis showing most significantly enriched pathways.
(C) Self-organizing heatmaps of the four hTERT-BMSC clones and five primary BMSC samples, including the parent population (FH181).
Arrows indicate presence (closed) and absence (open) of overrepresented (red) and underrepresented (blue) metagene spots.
(D) Heatmap showing expression of key genes involved in inflammatory-induced responses.
(legend continued on next page)
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differences of the inhibitory capacity of the cell lines at
each BMSC:PBMC ratio used (Figure S2E). Similar increases
in the expression of immunosuppressive factors (IDO1,
TGFB1, and CD274) following exposure to TNF-a and
IFN-g were observed in all hTERT-BMSC lines, but IL6
expression was significantly higher in the Y201 cells under
TNF-a/IFN-g stimulation (Figure S2F). Y102/Y202 cells
were significantly more responsive to inflammatory cyto-
kine-induced expression of factors involved in lymphocyte
homing and development, CXCL10 and IL-7. In particular,
basal mRNA expression of IL-7 in Y102/Y202 cells was
equivalent to expression levels in TNF-a/IFN-g-stimulated
Y101/Y201 cells (Figure S2F). IL-7 signaling was high-
lighted as a differentially regulated pathway (Figure 2B),
and we identified strong expression of IL-7 in Y102/Y102
compared to low IL-7 levels in Y101/Y201 by immunocyto-
chemistry (Figure 2E). Using ELISAs, we confirmed signifi-
cantly higher secretion of IL-7 in Y102/202 versus Y101/
Y201; heterogeneous primary BMSCs secreted low levels
of IL-7, with negligible expression in human dermal fibro-
blasts (Figure 2F). No difference in IL-7 receptor expression
level was observed by flow cytometry across the four cell
lines (data not shown).
Together, these data indicate that OAC-competent BMSC
clones expressed an extensive gene set consistent with
vascular interaction; all BMSC lines showed broadly similar
immunosuppressive features, while the poorly differen-
tiating hTERT-BMSCs displayed a striking constitutive
immunostimulatory expression profile and could be iden-
tified by elevated basal IL-7 expression, which has impor-
tant functions in lymphopoiesis (Ceredig and Rolink,
2012).
In Vivo Lineage Tracing of IL-7-Expressing Stromal
Cells
To identify and track IL-7-positive BMSC subpopulations
in vivo, we used an IL-7Cre Rosa26-EYFP lineage-tracing
mouse model, where enhanced yellow fluorescent protein
(EYFP) expression persists in the progeny of cells that
expressed IL-7 at any stage. EYFP-positive cells were found
in bonemarrow occasionally at perivascular and endosteal-
lining locations but broadly distributed throughout the
marrow with an 4% frequency (Figures 3A–3F and S3A).
Using flow cytometry to discriminate CD45-expressing
hematopoietic cells, we found the EYFP-positive stromal
fraction represented 0.9% of the marrow cell population(E) Immunocytochemical detection of IL-7 expression (red) by the
counterstain in blue). Scale bars, 20 mm.
(F) IL-7 expression by ELISA in the four hTERT-BMSC clones, primary B
Data represent mean values ± SD from three individual experiments p
See also Figure S2.
Stem C(Figure S3B). From histological sections, 91%, 77%, and
92%, respectively, of femoral, tibial, and calvarial osteo-
cytes, terminally differentiated cells of the osteogenic line-
age (Figures 3D–3F and S3A), and all perilipin-positive bone
marrow cells and all adipocytes in white adipose tissue
examined were EYFP negative (Figures 3G–3L and S3C).
Strong EYFP positivity was confirmed in 11%–60% of artic-
ular chondrocytes (Figures 3M–3O and S3A), where IL-7
expression has been previously identified (Long et al.,
2008), and in 7%–31% of hypertrophic chondrocytes (Fig-
ure S3A). These data demonstrate that a substantial propor-
tion of mesodermal-derived adipose, bone, and cartilage
tissues originate from a progenitor cell type that at no point
expressed IL-7 and support the existence of poorly/non-
differentiating IL-7hi BMSC subtype in vivo.
Identification of Y102/Y202-Related Subtypes in
Primary BMSCs
Y101/Y201 and Y102/Y202 lines were screened by flow
cytometry in an attempt to identify a distinguishing
cell-surface protein to sort from primary BMSC popula-
tions. We found little difference in expression of candidate
BMSC markers CD271, CD51, and PDGFRa; while CD146
was largely undetectable on the Y201 line, its expres-
sion was similar in the other BMSC clones (Figure 4A).
LepR/CD295 was expressed by both OAC-differentiating
lines and the differentiation-incompetent lines (Figure 4A);
in murine bone marrow, LepR/CD295 expression was
found to be predominantly, though not exclusively, ex-
pressed by bone- and adipocyte-forming BMSCs (Zhou
et al., 2014).
We analyzed the array data for differential expression
of genes encoding cell-surface proteins; while ICAM1
and CD274 had similar protein expression profiles across
all lines, CD317 was selectively and highly expressed in
Y102 and Y202 cells and absent from Y101 and Y201
cells (Figure 4A). We examined another four BMSC
clones (Y204, Y205, Y301, and Y302) generated during
the initial hTERT immortalization experiments (Fig-
ure S4A). They exhibited varying degrees of differentia-
tion potency (Figures S4B–S4H), but none were differen-
tiation incompetent across osteogenic, adipogenic, and
chondrogenic lineages to the same degree as observed
for Y102/Y202, and all were negative for CD317 (Fig-
ure S4I). CD317 (also known as BST2/tetherin) has re-
cognized anti-viral properties (Hotter et al., 2013), andfour hTERT-BMSC clones (after 24 hr in culture) (DAPI nuclear
MSCs (K98, K102, and K110), and human dermal fibroblasts (HDF).
erformed in duplicate.
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Y102/Y202 cells expressed elevated levels of several other
anti-viral genes compared to Y101/Y201 and parent
BMSCs (Figure 4B).
In low passage, primary BMSCs, a CD317-expressing
population was detected in 1%–3% of the total cells (Fig-
ure S4J). We used fluorescence-activated cell sorting (FACS)
to sort the CD317+ fraction from CD317 cells for further
analysis and found that CD317+ cells were capable of
density-independent growth and formed CFU fibroblasts
(CFU-F) at a frequency similar to CD317 cells (Figure 4C).
Morphological analysis of individual colonies identified
that CD317+ cells had statistically significantly increased
cell perimeters (1,042 ± 309 mm) and areas (5,355 ±
1,306 mm) compared to CD317 cells (1,386 ± 638 mm
and 330 ± 154 mm, respectively) (Figures 4D and S4K), mir-
roring Y102/Y202 versus Y102/Y201 size differences. Using
qPCR and ELISA, we confirmed that CD317+ BMSCs
expressed significantly elevated IL-7 mRNA and secreted
more IL-7 protein than the CD317 population (Figure 4E),
with limited evidence that CD317+ cells have elevated
basal mRNA expression levels of immunosuppressive fac-
tors compared to CD317 cells (Figure S4L), while exposure
of primary BMSCs to IFN-g for 24 hr resulted in an 3-fold
increase in CD317 expression (Figure S4M). As marker
expression can change with time in culture, we also sorted
CD317-expressing cells from fresh, whole human bone
marrow mononuclear cells (BM-MNCs); CD317+ cells in
the stromal CD45CD31 population represented on
average 0.4% of the live cell population from two donors
(Figures S4N and S4O).
In mouse tissue sections, CD317 was expressed sporadi-
cally throughout the bone marrow (Figures 4F and S4P;
isotypecontrol is showninFigureS4Q).CD317-positive cells
rarely associated with CD31-positive vascular cells (Figures
4F and S4P) and did not generally colocalize with Cxcl12-
DsRed+perivascular stromalandendothelial cells (Figure4F).
The majority of bone marrow LepR-expressing cells lacked
CD317 expression, though occasional LepR+CD317+ cells
were identified (Figure 4G).
Collectively, these findings identify the presence of a
rare, colony-forming population of BMSCs, marked by
CD317 positivity, which appear to have an enhanced im-
munostimulatory capacity and are closely related to the
Y102 and Y202 phenotype. We employed Raman spec-Figure 3. Lineage Tracing of IL-7-Expressing Cells Using IL-7cre
(A–F) Sporadic EYFP expression throughout bone marrow, associate
prominent on endosteal surfaces (B). Infrequent osteocytes were EYF
(G–J) Immunostaining of perilipin-positive adipocytes (red) in bone
(K and L) Absence of EYFP expression in white adipose tissue extract
(M–O) EYFP expression in chondrocytes of articular cartilage.
Scale bars, 50 mm (unless otherwise stated). See also Figure S3.
Stem Ctroscopy to determine the extent of this relationship
and provide a diagnostic evaluation of functional varia-
tion between BMSC subtypes. Averaged spectra were
generated for each hTERT clonal line and primary
CD317+ sorted BMSCs (Figure 4H), with their respective
peak assignments identified as described previously (Mo-
vasaghi et al., 2007; Schulze et al., 2010). Peak intensity
ratios were obtained between all identified peaks for
each cell type; the most discriminatory was found to be
against the 1,088.6 cm1 peaks. The 1,088.6 cm1 peak
is related to the symmetric phosphate stretch of the
DNA backbone (Movasaghi et al., 2007) with its discrimi-
nation signifying a fundamental difference in the DNA of
the cell types. This peak has also been used to discrimi-
nate other cell types, (Chan et al., 2006). The 966cm-1/
1088.6 cm1 peak intensity ratios distinguished Y101
from Y201 (Figure 4I, arrow). Other peak intensity ratios,
most notably from 999.6 cm1 and higher, clearly sepa-
rated Y101/Y201 from Y102/Y202 (Figure 4I). Impor-
tantly, primary CD317+ cells mapped with remarkable
consistency to the Y102/Y202 Raman profile (Figure 4I),
providing strong evidence of relatedness.DISCUSSION
We generated immortalized BMSC clones to perform
detailed analysis of functional diversity in BMSC subtypes
to levels not previously described. Similar immortalization
techniques (e.g., hTERT combined with human papilloma-
virus E6/E7) have been used for the clonal analysis of
BMSCs, which found OAC, AO, OC, unipotent, and nulli-
potent clones at varied frequencies, but other functional
characteristics and discriminating features were not exam-
ined (Larsen et al., 2010; Okamoto et al., 2002). Notably,
however, enhanced immune-related features could be as-
signed to non-bone-forming hTERT-BMSCs in a previous
study (Larsen et al., 2010). Using non-immortalized
BMSC clones, Muraglia et al. identified OAC-, OC-, and
O-competent lines only, with very rare (<1%) nullipotent
subsets (Muraglia et al., 2000). Rather than determine
occurrence of O/A/C phenotypes in heterogeneous BMSCs,
here our aim was to identify molecular and biophys-
ical markers of BMSC subtypes and their alignment withRosa26-EYFP Mice
d occasionally with cells lining the vasculature (A, arrows) and
P positive (D–F).
marrow of IL-7cre Rosa26-EYFP mice.
ed from IL-7cre Rosa26-EYFP mice.
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Figure 4. Identification of CD317+ Bone Marrow Cells
(A) Flow cytometric analysis of hTERT-BMSC; CD317 expression selectively discriminates Y102/Y202 from Y101/Y201.
(B) Heatmap showing expression of key genes involved in anti-viral responses.
(C) CFU-F assay and morphology of CD317 and CD317+ cells sorted from heterogeneous BMSCs. Scale bars, 200 mm. Histogram represents
mean ± SEM (n = 4 independent experiments performed with five replicates).
(legend continued on next page)
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non-progenitor cell functions, including immunomodula-
tory properties. To this end, from the original hTERT-BMSC
lines generated, we selected four clones positioned at
opposing ends of a differentiation competency scale, tripo-
tent Y101/Y201 and relatively impotent Y102/Y202, for
in-depth cell profiling. The OAC-differentiating lines ex-
pressed an extensive and significantly enriched gene set
consistent with blood vessel support/interaction compared
to nullipotent clones. This may reflect a relationship be-
tween BMSC differentiation competency and a perivascu-
lar niche location (Sacchetti et al., 2007). Conversely,
Y102 and Y202 lines expressed CD antigens widely used
to describe BMSCs (Dominici et al., 2006; Pittenger et al.,
1999) but exhibited very little differentiation capacity. Sub-
sequent assays revealed that an equivalent CD317+ cell
type existed in heterogeneous primary BMSC populations
at1%–3% frequency and CD45CD31CD317+ cells rep-
resented 0.4% of whole human BM-MNCs. Primary cell
analysis and in vivo validation is an important component
of our study. Data obtained using in vitro immortalized cell
lines must be interpreted with some caution, considering
the effects of hTERT transduction artifacts. Integration
site, enhanced telomerase activity and long-term culture
are all likely to impact on cell function. We attempted to
minimize potential confounding effects by selecting two
cell lines, each displaying similar properties (Y101/Y201
and Y102/Y202). We used Raman spectroscopy, which
has been demonstrated as a non-destructive label-free
method to study the biological state of single cells and to
identify molecular-scale differences for cell discrimination
(see Schulze et al., 2010, for example). In this work,
Raman spectroscopy was able to uniquely identify the
four hTERT-BMSC clones, separating Y101 from Y201
and confirming a striking biomolecular relationship
between Y102/Y202 and primary CD317+ cells, which
also shared an enlarged, spread morphology, forming
compact, non-migratory colonies. We performed detailed
bioinformatics to scrutinize gene expression profiles
against the parental BMSCs. These analyses ultimately
identified the closely clustered Y102 and Y202 lines as
having remarkably high basal level expression of factors(D) Analysis of cell perimeter (left) and cell area (right) of CD317 and
independent experiments in which, on average, 113 cells were exami
(E) IL-7 mRNA (left) and protein expression (right, by ELISA) in CD3
FACS-sorted cells in triplicate from four or two donors, respectively.
(F) Immunohistochemistry of mouse femur bone marrow sections stain
(white) and nuclear (DAPI, blue) staining. Representative merged an
(G) Immunolocalization of LepR/CD295 (green) and CD317 (red) in m
sional dual LepR+CD317+ cells (lower panel). Blue indicates nuclear D
(H and I) Analysis of hTERT-BMSC clones and CD317+ cells by Raman sp
peak assignments are provided in Table S2.
See also Figure S4.
Stem Cassociated with a pro-inflammatory and anti-viral func-
tion. The significantly enriched gene sets we identified
in unchallenged Y102/Y202 BMSC lines are typical of an
immediate immunostimulatory response to infection
and other insults. Notably, all BMSC clones exhibited
similar inhibitory effects on PBMC proliferation when
activated by exposure to anti-CD3 and anti-CD28 tomimic
antigen presentation. Consequently, Y102/Y202 BMSC
subtypes may function in both immunostimulatory (early,
pro-inflammatory) and immunosuppressive (anti-inflam-
matory, tissue protective) responses depending on the im-
mune environment; however, functional validation and
further refinement of the characteristics of this CD317-ex-
pressing population is required. Dual immunomodulatory
functions for BMSCs have been identified and discussed
(Dazzi and Krampera, 2011), but not assigned to BMSC
subtypes. CD317+ cells (as well as Y102/Y202) were charac-
terized as having elevated IL-7 expression, which has well-
established roles in T and B cell development (Ceredig and
Rolink, 2012). Examination of skeletal tissues in a lineage-
tracing mouse model confirmed that a substantial subpop-
ulation of the differentiated progeny of BMSCs could not
have arisen from IL-7-expressing stromal progenitors. It
should be noted that differentiated skeletal cells may ex-
press IL-7 (Long et al., 2008; Zhu et al., 2007), which would
also be revealed as EYFP positivity. However, these studies
provide unequivocal evidence linking IL-7 expression in
stromal subsets with differentiation incompetence during
normal development in vivo. Our in vivo observations
were reflected in our in vitro assays of differentiation,
where the IL-7hi immortalized BMSC clones (Y102/Y202)
exhibited limited skeletogenic potential. These in vitro as-
says are prone to artifact that could result in non-specific
detection of widely used markers of differentiation that
may not report authentic in vivo differentiation capacity,
observed for example using in vivo transplantation tech-
niques (Robey et al., 2014). Evenwith these caveats, we still
failed to detect clear evidence of differentiation ability in
Y102/Y202 CD317+ IL-7hi BMSC lines. In vivo, CD317+
cells had a dispersed bone marrow distribution and did
not generally colocalize with Cxcl12-DsRed+ perivascularCD317+ cells sorted from heterogeneous BMSCs. Mean ± SEM, n = 4
ned. *p < 0.05 by unpaired non-parametric t test.
17 and CD317+ cells. Data represent mean IL-7 levels ± SD from
*p < 0.05 by paired t test.
ed with antibodies to CD317 (red), CD31 (green) with Cxcl12-DsRed
d single-panel images shown.
ouse bone marrow showing LepR+CD317 (upper panel) and occa-
API stain.
ectroscopy, Raman shifts (H) and peak ratios (I) are shown. Raman
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stromal cells, again pointing to an alternative function
for CD317+ BMSCs, unrelated to CXCL12-mediated he-
matopoietic stem cell niche support. CD317 has a well-
defined anti-viral function acting to tether and restrict
the release of viral particles and may also trigger the viral
immune response (Hotter et al., 2013). The existence of a
marrow-resident, non-migratory, non-differentiating col-
ony-forming stromal cell type, apparently primed for
host defense, is an interesting concept. These cells could
act as first responders to pathogen invasion and/or pro-
vide low-level immune control. As IL-7 has been impli-
cated as a causative factor in autoimmunity, including
rheumatoid arthritis (Dooms, 2013), unregulated control
of CD317+ cell numbers and function may also contribute
to disease onset and progression. These findings highlight
the importance of identifying unique markers of BMSC
sub-populations and assigning function, which will
instruct strategies to analyze stromal-immune cell interac-
tion, differentiation competency, and cell selection for
safe and effective therapy.EXPERIMENTAL PROCEDURES
Primary BMSC Isolation, Culture, and hTERT BMSC
Production
All animal experiments and work involving human samples were
approved by the University of York, Department of Biology ethics
committee. Primary human BMSCs were isolated from femoral
heads obtained with informed consent during routine hip
replacement (see the Supplemental Experimental Procedures) or
as explant cultures from human tibial plateaus after routine
knee replacement. Cells were cultured in DMEM containing
15% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml
streptomycin (changed every 3–4 days); cells were passaged at
70%–80% confluency. Cells were expanded and used between
passage 1 (p1) and p5.
The hTERT lentiviral vector was produced using ViraPower
Lentiviral Gateway Expression Kit (Invitrogen), according to the
manufacturer’s guidelines, before transduction into primary hu-
man BMSCs isolated at p3 from the femoral head of a single donor.
For selection of single cell lines, the transduced BMSCswere trypsi-
nized and plated at 10 cells/cm2. Cells were grown in BMSC
medium containing 20%HyClone serum at plating, then replaced
with freshmedia containing 15%HyClone serum every 3 or 4 days
to day 14 (until discrete single-cell colonies were visible). Single-
cell colonies were isolated and expanded.
For further information, see Supplemental Experimental
Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and three tables and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2015.05.
005.1014 Stem Cell Reports j Vol. 4 j 1004–1015 j June 9, 2015 j ª2015 The AutAUTHOR CONTRIBUTIONS
S.J. and J.F. performed experiments and designed the studies. F.A.,
M.H., S.C., J.L., and C.K. performed in vitro experiments; J.A. and
P.A. performed the bioinformatics analyses; and O.P., S.C., and
M.C. provided and analysed in vivo data. R.D.A.R.P. and Y.H. de-
signed and analysed the Raman work. P.G. supervised the work
and designed experiments. All authors contributed to writing the
paper, which was led by J.F., S.J., and P.G.
ACKNOWLEDGMENTS
Arthritis Research UK Tissue Engineering Centre (19429), Biotech-
nology and Biological Sciences Research Council, the Dr. Hadwen
Trust and Medical Research Council (G0601156), and a CNPq
(Brazil) PhD scholarship funded the work. We thank Florian
Gruber for assistance with CellProfiler analysis. We are grateful to
staff and patients of Clifton Park Hospital for samples.
Received: July 30, 2014
Revised: May 5, 2015
Accepted: May 5, 2015
Published: June 9, 2015REFERENCES
Ceredig, R., and Rolink, A.G. (2012). The key role of IL-7 in lym-
phopoiesis. Semin. Immunol. 24, 159–164.
Chan, J.W., Taylor, D.S., Zwerdling, T., Lane, S.M., Ihara, K.,
and Huser, T. (2006). Micro-Raman spectroscopy detects indi-
vidual neoplastic and normal hematopoietic cells. Biophys. J.
90, 648–656.
Crop, M.J., Baan, C.C., Korevaar, S.S., Ijzermans, J.N., Pescatori,
M., Stubbs, A.P., van Ijcken, W.F., Dahlke, M.H., Eggenhofer, E.,
Weimar, W., and Hoogduijn, M.J. (2010). Inflammatory condi-
tions affect gene expression and function of human adipose tis-
sue-derived mesenchymal stem cells. Clin. Exp. Immunol. 162,
474–486.
Dazzi, F., and Krampera, M. (2011). Mesenchymal stem cells and
autoimmune diseases. Best Pract. Res. Clin. Haematol. 24, 49–57.
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Mar-
ini, F., Krause, D., Deans, R., Keating, A., Prockop, Dj., and Hor-
witz, E.; The International Society for Cellular Therapy Position
Statement (2006). Minimal criteria for defining multipotent
mesenchymal stromal cells. The International Society for Cellular
Therapy position statement. Cytotherapy 8, 315–317.
Dooms, H. (2013). Interleukin-7: Fuel for the autoimmune attack.
J. Autoimmun. 45, 40–48.
Hotter, D., Sauter, D., and Kirchhoff, F. (2013). Emerging role of the
host restriction factor tetherin in viral immune sensing. J. Mol.
Biol. 425, 4956–4964.
Johnson, K., Zhu, S., Tremblay, M.S., Payette, J.N., Wang, J., Bou-
chez, L.C.,Meeusen, S., Althage, A., Cho, C.Y.,Wu, X., and Schultz,
P.G. (2012). A stem cell-based approach to cartilage repair. Science
336, 717–721.
Kuznetsov, S.A., Krebsbach, P.H., Satomura, K., Kerr, J., Riminucci,
M., Benayahu, D., and Robey, P.G. (1997). Single-colony derivedhors
strains of humanmarrow stromal fibroblasts form bone after trans-
plantation in vivo. J. Bone Miner. Res. 12, 1335–1347.
Larsen, K.H., Frederiksen, C.M., Burns, J.S., Abdallah, B.M., and
Kassem, M. (2010). Identifying a molecular phenotype for bone
marrow stromal cells with in vivo bone-forming capacity. J. Bone
Miner. Res. 25, 796–808.
Long, D., Blake, S., Song, X.Y., Lark,M., and Loeser, R.F. (2008). Hu-
man articular chondrocytes produce IL-7 and respond to IL-7 with
increased production of matrix metalloproteinase-13. Arthritis
Res. Ther. 10, R23.
Mabuchi, Y.,Morikawa, S., Harada, S., Niibe, K., Suzuki, S., Renault-
Mihara, F.,Houlihan,D.D.,Akazawa,C.,Okano,H., andMatsuzaki,
Y. (2013). LNGFR(+)THY-1(+)VCAM-1(hi+) cells reveal functionally
distinct subpopulations in mesenchymal stem cells. Stem Cell
Reports 1, 152–165.
Me´ndez-Ferrer, S., Michurina, T.V., Ferraro, F., Mazloom, A.R.,Mac-
arthur, B.D., Lira, S.A., Scadden, D.T., Ma’ayan, A., Enikolopov,
G.N., and Frenette, P.S. (2010). Mesenchymal and haematopoietic
stemcells form a unique bonemarrowniche.Nature 466, 829–834.
Movasaghi, Z., Rehman, S., and Rehman, I.U. (2007). Raman spec-
troscopy of biological tissues. Appl. Spectrosc. Rev. 42, 493–541.
Muraglia, A., Cancedda, R., and Quarto, R. (2000). Clonal mesen-
chymal progenitors from human bone marrow differentiate
in vitro according to a hierarchical model. J. Cell Sci. 113, 1161–
1166.
Nauta, A.J., and Fibbe,W.E. (2007). Immunomodulatory properties
of mesenchymal stromal cells. Blood 110, 3499–3506.
Okamoto, T., Aoyama, T., Nakayama, T., Nakamata, T., Hosaka, T.,
Nishijo, K., Nakamura, T., Kiyono, T., and Toguchida, J. (2002).
Clonal heterogeneity in differentiation potential of immortalized
human mesenchymal stem cells. Biochem. Biophys. Res. Com-
mun. 295, 354–361.
Pinho, S., Lacombe, J., Hanoun, M., Mizoguchi, T., Bruns, I., Kuni-
saki, Y., and Frenette, P.S. (2013). PDGFRa and CD51 mark human
nestin+ sphere-forming mesenchymal stem cells capable of he-
matopoietic progenitor cell expansion. J. Exp. Med. 210, 1351–
1367.
Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R.,
Mosca, J.D., Moorman, M.A., Simonetti, D.W., Craig, S., and
Marshak, D.R. (1999). Multilineage potential of adult human
mesenchymal stem cells. Science 284, 143–147.Stem CQuirici, N., Soligo, D., Bossolasco, P., Servida, F., Lumini, C., and
Deliliers, G.L. (2002). Isolation of bone marrow mesenchymal
stem cells by anti-nerve growth factor receptor antibodies. Exp.
Hematol. 30, 783–791.
Robey, P.G., Kuznetsov, S.A., Riminucci, M., and Bianco, P. (2014).
Bone marrow stromal cell assays: in vitro and in vivo. Methods
Mol. Biol. 1130, 279–293.
Russell, K.C., Phinney, D.G., Lacey, M.R., Barrilleaux, B.L., Meyer-
tholen, K.E., and O’Connor, K.C. (2010). In vitro high-capacity
assay to quantify the clonal heterogeneity in trilineage potential
of mesenchymal stem cells reveals a complex hierarchy of lineage
commitment. Stem Cells 28, 788–798.
Russell, K.C., Lacey, M.R., Gilliam, J.K., Tucker, H.A., Phinney,
D.G., and O’Connor, K.C. (2011). Clonal analysis of the prolifera-
tion potential of humanbonemarrowmesenchymal stem cells as a
function of potency. Biotechnol. Bioeng. 108, 2716–2726.
Sacchetti, B., Funari, A., Michienzi, S., Di Cesare, S., Piersanti, S.,
Saggio, I., Tagliafico, E., Ferrari, S., Robey, P.G., Riminucci, M.,
and Bianco, P. (2007). Self-renewing osteoprogenitors in bone
marrow sinusoids can organize a hematopoietic microenviron-
ment. Cell 131, 324–336.
Schulze, H.G., Konorov, S.O., Caron, N.J., Piret, J.M., Blades, M.W.,
and Turner, R.F. (2010). Assessing differentiation status of human
embryonic stem cells noninvasively using Raman microspectro-
scopy. Anal. Chem. 82, 5020–5027.
Serakinci, N., Guldberg, P., Burns, J.S., Abdallah, B., Schrødder, H.,
Jensen, T., and Kassem, M. (2004). Adult human mesenchymal
stem cell as a target for neoplastic transformation. Oncogene 23,
5095–5098.
Simmons, P.J., and Torok-Storb, B. (1991). Identification of stromal
cell precursors in human bone marrow by a novel monoclonal
antibody, STRO-1. Blood 78, 55–62.
Zhou, B.O., Yue, R., Murphy, M.M., Peyer, J.G., and Morrison, S.J.
(2014). Leptin-receptor-expressing mesenchymal stromal cells
represent the main source of bone formed by adult bone marrow.
Cell Stem Cell 15, 154–168.
Zhu, J., Garrett, R., Jung, Y., Zhang, Y., Kim, N., Wang, J., Joe, G.J.,
Hexner, E., Choi, Y., Taichman, R.S., and Emerson, S.G. (2007).
Osteoblasts support B-lymphocyte commitment and differentia-
tion from hematopoietic stem cells. Blood 109, 3706–3712.ell Reports j Vol. 4 j 1004–1015 j June 9, 2015 j ª2015 The Authors 1015
